KUALA LUMPUR, July 27 (Bernama) -- Prestige Biopharma Limited (Prestige) and Intas Pharmaceuticals Limited (Intas) have entered into a binding agreement for the exclusive partnership and supply for the commercialisation of Prestige Biopharma’s bevacizumab biosimilar.
This is for commercialisation in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan and Tajikistan, according to a statement.
The partnership arrangement includes the exclusive rights for Intas and its affiliate Accord Healthcare that will commercialise the bevacizumab biosimilar in these countries.
This collaboration represents the successful execution of the company’s strategy to expand its market reach in Europe and Canada leveraging Accord’s strong global footprint and deep commercial expertise.
Prestige Biopharma’s chief executive officer Lisa S. Park said: “We are delighted to establish a partnership with Intas for the key markets, the US and Europe.
“Accord is the ideal partner to commercialise our bevacizumab biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programmes in global markets.”
Prestige’s bevacizumab (HD204) is a mAb biosimilar to Roche’s Avastin®, an inhibitor of vascular endothelial growth factor (VEGF), which is used in combination with other therapies to treat patients with multiple forms of cancer.
Prestige’s HD204 with excellent cost competitiveness based on the company’s proprietary bevacizumab production technology will be providing affordable access to more patients in need.
More details at www.prestigebiopharma.com.
-- BERNAMA
No comments:
Post a Comment